Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus KEFLIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus KEFLIN IN PLASTIC CONTAINER.
AVYCAZ vs KEFLIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity, leading to cell lysis and death.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
1 to 2 g IV or IM every 4 to 6 hours. Maximum 12 g/day.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
0.5-1 hour in normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min)
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Renal: 60-80% unchanged; biliary/fecal: minimal (<1%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic